001445966 000__ 05462cam\a2200601\a\4500
001445966 001__ 1445966
001445966 003__ OCoLC
001445966 005__ 20230310003930.0
001445966 006__ m\\\\\o\\d\\\\\\\\
001445966 007__ cr\un\nnnunnun
001445966 008__ 220416s2022\\\\si\\\\\\o\\\\\000\0\eng\d
001445966 019__ $$a1311164669$$a1311240501$$a1311269440$$a1311358419$$a1311464211
001445966 020__ $$a9789811687020$$q(electronic bk.)
001445966 020__ $$a9811687021$$q(electronic bk.)
001445966 020__ $$z9811687013
001445966 020__ $$z9789811687013
001445966 0247_ $$a10.1007/978-981-16-8702-0$$2doi
001445966 035__ $$aSP(OCoLC)1311312658
001445966 040__ $$aEBLCP$$beng$$epn$$cEBLCP$$dGW5XE$$dYDX$$dEBLCP$$dOCLCO$$dOCLCF$$dOCLCQ$$dN$T$$dUKAHL$$dOCLCQ
001445966 049__ $$aISEA
001445966 050_4 $$aQR370
001445966 08204 $$a579.2$$223/eng/20220420
001445966 24500 $$aVirus entry inhibitors :$$bstopping the enemy at the gate /$$cShibo Jiang, Lu Lu, editors.
001445966 260__ $$aSingapore :$$bSpringer,$$c2022.
001445966 300__ $$a1 online resource (242 pages)
001445966 336__ $$atext$$btxt$$2rdacontent
001445966 337__ $$acomputer$$bc$$2rdamedia
001445966 338__ $$aonline resource$$bcr$$2rdacarrier
001445966 4901_ $$aAdvances in Experimental Medicine and Biology ;$$vv. 1366
001445966 500__ $$a5.2.2 LL-37.
001445966 5050_ $$aIntro -- Preface -- Acknowledgments -- Contents -- 1: Virus Entry Inhibitors: Past, Present, and Future -- 1.1 Introduction -- 1.2 Peptide-Based Virus Entry Inhibitors -- 1.2.1 Viral Fusion Protein Targeting -- 1.2.2 Host Protein or Pathway Targeting -- 1.2.3 The Future of Peptide-Based Virus Entry Inhibitors -- 1.3 Small-Molecule-Based Virus Entry Inhibitors -- 1.3.1 Viral Fusion Protein Targeting -- 1.3.2 Host Protein or Pathway Targeting -- 1.3.3 The Future of Small-Molecule-Based Virus Entry Inhibitors -- 1.4 Protein-Based Virus Entry Inhibitors -- 1.4.1 Viral Fusion Protein Targeting
001445966 5058_ $$a1.4.2 Host Protein or Pathway Targeting -- 1.4.3 The Future of Protein-Based Virus Entry Inhibitors -- 1.5 Conclusion and Prospect -- References -- 2: Peptide-Based HIV Entry Inhibitors -- 2.1 Introduction -- 2.2 Peptides Targeting Cellular Receptors -- 2.3 Peptides Targeting Virus -- 2.3.1 Peptides Targeting CD4-Binding Site (CD4bs) or Co-Receptor-Binding Site (CoRbs) in the HIV-1 gp120 -- 2.3.2 Peptides Inactivating Cell-Free Virions -- 2.4 Peptides Blocking Virus-Cell or Cell-Cell Fusion -- 2.4.1 Peptides Targeting Fusion Peptide (FP) in gp41
001445966 5058_ $$a2.4.2 Peptide Blocking Six-Helix Bundle (6-HB) Formation -- 2.4.3 Peptides Targeting the Disulfide Loop Region of gp41 -- 2.5 Conclusion -- References -- 3: Small-Molecule HIV Entry Inhibitors Targeting gp120 and gp41 -- 3.1 Structure and Function of gp120 and gp41 -- 3.2 Small-Molecule HIV-1 Entry Inhibitors Targeting gp120 -- 3.2.1 NBD-556 and Analogs -- 3.2.2 CD4 Mimics Binding Competitively with gp120 Suppress the Binding of gp120 to CD4 -- 3.2.3 The Acylhydrazone-Containing Small Molecule 18A -- 3.3 Small-Molecule HIV Entry Inhibitors Target gp41 -- 3.3.1 ADS-J1 and Its Resistance Profile
001445966 5058_ $$a3.3.2 NB-2, NB-64, A12, GLS-22, and Analogs -- 3.3.3 NB-206, 12m and Analogs -- 3.3.4 Indole-Based Compounds, as Small-Molecule HIV-1 Fusion Inhibitors Targeting gp41, Identified -- 3.3.5 5M038, 5M041 and Analogs Identified by Fluorescence Polarization Assay Using gp41-5 as the Target -- 3.3.6 Alpha-Helical Mimicry and Colorimetric, Affinity-Based Selection Assay -- 3.3.7 Natural Polyanionic Ingredient -- 3.4 Future of HIV-1 Small-Molecule Entry/Fusion Inhibitors and Screening Assay -- References -- 4: The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors
001445966 5058_ $$a4.1 Introduction -- 4.2 Discovery and SAR of Fostemsavir-Related Series (BMS Series) -- 4.3 Alternate Chemotypes for Targeting gp120 Unrelated to Keto Amides -- 4.4 Application of HIV gp120 Inhibitors -- 4.4.1 As Microbicides -- 4.4.2 As Target Recognition Element in Conjugates -- 4.4.3 As Immuno-Protectants or Immuno-Stimulators -- 4.4.4 As Agents Against Cytopathic and Non-cytopathic Effects of gp120 -- 4.5 Future Directions -- 4.6 Conclusions -- References -- 5: Endogenous Peptide Inhibitors of HIV Entry -- 5.1 Introduction -- 5.2 Antiviral Host Defense Peptides -- 5.2.1 Defensins
001445966 506__ $$aAccess limited to authorized users.
001445966 520__ $$aThis book focuses on the important discoveries of the small molecule-, peptide-, and protein-based virus entry inhibitors and discusses advance of the development of different type of virus entry inhibitors as a novel class of antiviral drugs for treatment and prevention of viral infection. It includes entry inhibitors of HIV, HeV, NiV, RSV, EBOV, HCoV, HBV, HCV, HDV, HPV, flavivirus and influenza virus, so on. This book aims at providing an updated knowledge on virus entry inhibitors.
001445966 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed April 20, 2022).
001445966 650_0 $$aVirus inhibitors.
001445966 650_0 $$aViruses.
001445966 650_6 $$aVirus$$xInhibiteurs.
001445966 650_6 $$aVirus.
001445966 655_0 $$aElectronic books.
001445966 7001_ $$aJiang, Shibo.
001445966 7001_ $$aLu, Lu.
001445966 77608 $$iPrint version:$$aJiang, Shibo.$$tVirus Entry Inhibitors.$$dSingapore : Springer Singapore Pte. Limited, ©2022$$z9789811687013
001445966 830_0 $$aAdvances in experimental medicine and biology ;$$vv. 1366.
001445966 852__ $$bebk
001445966 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-981-16-8702-0$$zOnline Access$$91397441.1
001445966 909CO $$ooai:library.usi.edu:1445966$$pGLOBAL_SET
001445966 980__ $$aBIB
001445966 980__ $$aEBOOK
001445966 982__ $$aEbook
001445966 983__ $$aOnline
001445966 994__ $$a92$$bISE